Constantine S Mitsiades

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi Mouse models of human myeloma
    Constantine S Mitsiades
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Hematol Oncol Clin North Am 21:1051-69, viii. 2007
  2. ncbi Antimyeloma activity of heat shock protein-90 inhibition
    Constantine S Mitsiades
    Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Harvard Medical School, Boston MA 02115, USA
    Blood 107:1092-100. 2006
  3. ncbi CD44v6, a target for novel antibody treatment approaches, is frequently expressed in multiple myeloma and associated with deletion of chromosome arm 13q
    Constantine S Mitsiades
    Dept. of Medical Oncology, Dana-Farber Cancer Institute, Dept. of Medicine, Harvard Medical School, Boston, Mass, USA
    Haematologica 90:436-7. 2005
  4. ncbi Targeting BRAFV600E in thyroid carcinoma: therapeutic implications
    Constantine S Mitsiades
    Department of Medical Oncology, Dana Farber Cancer Institute, Mayer Building, Room M555, 44 Binney Street, Boston, MA 02115, USA
    Mol Cancer Ther 6:1070-8. 2007
  5. ncbi Fas signaling in thyroid carcinomas is diverted from apoptosis to proliferation
    Constantine S Mitsiades
    Department of Medical Oncology, Dana Farber Cancer Institute, Room M555, Mayer Building, 44 Binney Street, Boston, MA 02115, USA
    Clin Cancer Res 12:3705-12. 2006
  6. ncbi Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications
    Constantine S Mitsiades
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Res 63:6689-96. 2003
  7. ncbi Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis
    Constantine S Mitsiades
    Department of Medical Oncology, Dana Farber Cancer Institute, Mayer Building, Room M555, 44 Binney Street, Boston, Massachusetts 02115, USA
    J Clin Endocrinol Metab 91:3662-6. 2006
  8. ncbi Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications
    Constantine S Mitsiades
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 101:540-5. 2004
  9. ncbi Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors
    Constantine S Mitsiades
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Cancer Cell 5:221-30. 2004
  10. ncbi Proteasome inhibition as a new therapeutic principle in hematological malignancies
    Constantine S Mitsiades
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Curr Drug Targets 7:1341-7. 2006

Detail Information

Publications85

  1. ncbi Mouse models of human myeloma
    Constantine S Mitsiades
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Hematol Oncol Clin North Am 21:1051-69, viii. 2007
    ..Here we review the recent developments in the generation of mouse models of MM and their impact as preclinical models for designing and assessing target-based therapeutic approaches...
  2. ncbi Antimyeloma activity of heat shock protein-90 inhibition
    Constantine S Mitsiades
    Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Harvard Medical School, Boston MA 02115, USA
    Blood 107:1092-100. 2006
    ....
  3. ncbi CD44v6, a target for novel antibody treatment approaches, is frequently expressed in multiple myeloma and associated with deletion of chromosome arm 13q
    Constantine S Mitsiades
    Dept. of Medical Oncology, Dana-Farber Cancer Institute, Dept. of Medicine, Harvard Medical School, Boston, Mass, USA
    Haematologica 90:436-7. 2005
  4. ncbi Targeting BRAFV600E in thyroid carcinoma: therapeutic implications
    Constantine S Mitsiades
    Department of Medical Oncology, Dana Farber Cancer Institute, Mayer Building, Room M555, 44 Binney Street, Boston, MA 02115, USA
    Mol Cancer Ther 6:1070-8. 2007
    ..Small molecule inhibitors that selectively target B-Raf(V600E) may provide clinical benefit for patients with thyroid cancer...
  5. ncbi Fas signaling in thyroid carcinomas is diverted from apoptosis to proliferation
    Constantine S Mitsiades
    Department of Medical Oncology, Dana Farber Cancer Institute, Room M555, Mayer Building, 44 Binney Street, Boston, MA 02115, USA
    Clin Cancer Res 12:3705-12. 2006
    ..The death receptor Fas is present in thyroid carcinomas, yet fails to trigger apoptosis. Interestingly, Fas has been reported to be actually overexpressed in papillary thyroid carcinomas, suggesting that it may confer a survival advantage...
  6. ncbi Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications
    Constantine S Mitsiades
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Res 63:6689-96. 2003
    ..It therefore provides a valuable in vivo system to elucidate the molecular mechanisms underlying the marked osteotropism of MM, particularly for the axial skeleton, and for assessment of in vivo activity of novel anti-MM therapeutics...
  7. ncbi Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis
    Constantine S Mitsiades
    Department of Medical Oncology, Dana Farber Cancer Institute, Mayer Building, Room M555, 44 Binney Street, Boston, Massachusetts 02115, USA
    J Clin Endocrinol Metab 91:3662-6. 2006
    ..EGFR inhibitors have produced objective responses in patients with non-small-cell lung carcinomas harboring activating EGFR TK domain somatic mutations...
  8. ncbi Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications
    Constantine S Mitsiades
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 101:540-5. 2004
    ..These findings highlight the pleiotropic antitumor effects of HDAC inhibition, and provide the framework for future clinical applications of SAHA to improve patient outcome in MM...
  9. ncbi Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors
    Constantine S Mitsiades
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Cancer Cell 5:221-30. 2004
    ....
  10. ncbi Proteasome inhibition as a new therapeutic principle in hematological malignancies
    Constantine S Mitsiades
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Curr Drug Targets 7:1341-7. 2006
    ....
  11. ncbi The Akt pathway: molecular targets for anti-cancer drug development
    Constantine S Mitsiades
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston MA 02115, USA
    Curr Cancer Drug Targets 4:235-56. 2004
    ....
  12. ncbi Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro
    Constantine S Mitsiades
    Department of Medical Oncology, Dana Farber Cancer Institute, Mayer Building, Room M555, 44 Binney Street, Boston, MA 02115, USA
    J Clin Endocrinol Metab 91:4013-21. 2006
    ..NF-kappaB has been implicated in the pathophysiology of the most aggressive forms of thyroid carcinoma, i.e. medullary and anaplastic...
  13. ncbi Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment
    Constantine S Mitsiades
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute and Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
    J Cell Biochem 101:950-68. 2007
    ....
  14. ncbi Bcl-2 overexpression in thyroid carcinoma cells increases sensitivity to Bcl-2 homology 3 domain inhibition
    Constantine S Mitsiades
    Department of Medical Oncology, Dana Farber Cancer Institute, Mayer Building, Room M555, 44 Binney Street, Boston, Massachusetts 02115, USA
    J Clin Endocrinol Metab 92:4845-52. 2007
    ..The Bcl-2 family of proteins regulates apoptosis in various models and may represent a promising therapeutic target in human malignancies...
  15. ncbi Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo
    Constantine S Mitsiades
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Res 68:5216-25. 2008
    ..The profile of the anti-MM activity of Aplidin in our preclinical models provided the framework for its clinical testing in MM, which has already provided favorable preliminary results...
  16. ncbi Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib
    Constantine S Mitsiades
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Semin Hematol 46:166-75. 2009
    ....
  17. ncbi Treatment of hematologic malignancies and solid tumors by inhibiting IGF receptor signaling
    Constantine S Mitsiades
    Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Department of Medicine, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Expert Rev Anticancer Ther 5:487-99. 2005
    ..g., monoclonal antibodies) aimed at suppressing the function of this critical pathway for tumor cell pathophysiology...
  18. ncbi Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias
    Constantine S Mitsiades
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 15:1210-21. 2009
    ..Further, given its antiadhesive properties, we evaluated whether defibrotide modulates the protection conferred to multiple myeloma cells by bone marrow stromal cells...
  19. ncbi Proteasome inhibition as a therapeutic strategy for hematologic malignancies
    Constantine S Mitsiades
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA, USA
    Expert Rev Anticancer Ther 5:465-76. 2005
    ....
  20. ncbi Proteasome inhibitors as therapeutics
    Constantine S Mitsiades
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Essays Biochem 41:205-18. 2005
    ....
  21. ncbi The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies
    Constantine S Mitsiades
    Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Hematol Oncol Clin North Am 21:1007-34, vii-viii. 2007
    ..This article summarizes the recent progress in characterization, at the molecular and cellular levels, of how the BM milieu interacts with MM cells and modifies their biologic behavior...
  22. ncbi Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma
    Constantine S Mitsiades
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 29:1916-23. 2011
    ..This review discusses these challenges, as well as potential strategies to address them, with the aim of making significant improvement in the clinical outcome of patients with MM...
  23. ncbi Molecular sequelae of histone deacetylase inhibition in human retinoblastoma cell lines: clinical implications
    Vassiliki Poulaki
    Department of Ophthalmology, Angiogenesis Laboratory, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, USA
    Invest Ophthalmol Vis Sci 50:4072-9. 2009
    ..Vorinostat has demonstrated significant anticancer activity against hematologic and solid tumors at doses well tolerated by patients and has been approved for the treatment of patients with cutaneous T-cell lymphoma...
  24. ncbi The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro
    Vassiliki Poulaki
    Angiogenesis Laser Laboratory, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts 02114, USA
    Invest Ophthalmol Vis Sci 48:4706-19. 2007
    ..NF-kappaB, which is constitutively active in human retinoblastoma cells and promotes their survival, represents a therapeutic target for patients with this malignancy...
  25. ncbi Regulation of vascular endothelial growth factor expression by insulin-like growth factor I in thyroid carcinomas
    Vassiliki Poulaki
    Angiogenesis Laboratory, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts 02114, USA
    J Clin Endocrinol Metab 88:5392-8. 2003
    ....
  26. ncbi Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications
    Constantine S Mitsiades
    Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, MA 02115, USA
    Oncogene 21:5673-83. 2002
    ..Importantly, they provide the basis for future clinical trials in MM combining conventional or novel agents with strategies designed to neutralize IGF-1...
  27. ncbi Molecular sequelae of proteasome inhibition in human multiple myeloma cells
    Nicholas Mitsiades
    Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 99:14374-9. 2002
    ..These data provide both insight into the molecular mechanisms of antitumor activity of PS-341 and the rationale for future clinical trials of PS-341, in combination with conventional and novel therapies, to improve patient outcome in MM...
  28. ncbi The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications
    Nicholas Mitsiades
    Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Blood 101:2377-80. 2003
    ..These studies, therefore, provide the framework for clinical use of this agent in combination with conventional chemotherapy...
  29. ncbi Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications
    Yu-Tzu Tai
    The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA
    Cancer Res 64:2846-52. 2004
    ..1S cells and patient MM cells. Taken together, these results provide the preclinical rationale for the evaluation of SGN-40 as a potential new therapy to improve patient outcome in MM...
  30. ncbi In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465
    Joseph M Negri
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Br J Haematol 147:672-6. 2009
    ..Combinations with dexamethasone (Dex), doxorubicin (Doxo) and bortezomib showed no antagonism. Our study highlights the potential role of the tumour microenvironment in modulating the activity of this drug class...
  31. ncbi Human retinoblastoma cells are resistant to apoptosis induced by death receptors: role of caspase-8 gene silencing
    Vassiliki Poulaki
    Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA 02114, USA
    Invest Ophthalmol Vis Sci 46:358-66. 2005
    ..TRAIL signals through its receptors DR4 and DR5, which can activate caspase-8 as well. This study was undertaken to investigate the functional status of the FasL and TRAIL apoptotic pathways in retinoblastoma (Rb) cells...
  32. ncbi FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance
    Hiroshi Yasui
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Res 65:7478-84. 2005
    ..These results suggest that FTY720 overcomes drug resistance in multiple myeloma cells and provide the rationale for its clinical evaluation to improve patient outcome in multiple myeloma...
  33. ncbi Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications
    Douglas W McMillin
    Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute Department of Medicine, Harvard Medical School, Boston Novartis Institutes for BioMedical Research, Cambridge, MA 02115, USA
    Br J Haematol 152:420-32. 2011
    ..These observations provide insight into the biological relevance of multi-targeted CDK inhibition in MM...
  34. ncbi Inhibition of Hsp90 attenuates inflammation in endotoxin-induced uveitis
    Vassiliki Poulaki
    Angiogenesis Laser Laboratory, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, 243 Charles St, Boston, MA 02114, USA
    FASEB J 21:2113-23. 2007
    ..17-AAG has demonstrated a favorable safety profile in clinical trials in cancer patients and represents a promising therapeutic agent for the treatment of inflammatory eye diseases...
  35. ncbi Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235
    Douglas W McMillin
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Res 69:5835-42. 2009
    ..g., dexamethasone and doxorubicin) or novel (e.g., bortezomib) anti-MM agents showed lack of antagonism. These results indicate that BEZ235 merits clinical testing, alone and in combination with other agents, in MM...
  36. ncbi Novel histone deacetylase inhibitors in the treatment of thyroid cancer
    Constantine S Mitsiades
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Clin Cancer Res 11:3958-65. 2005
    ..g., anaplastic and medullary thyroid carcinomas) for which limited, if any, therapeutic options are available...
  37. ncbi Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib
    Melissa G Ooi
    Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 15:7153-60. 2009
    ..The cis-imidazoline nutlin-3 can disrupt the p53-Hdm2 interaction and activate p53, inducing apoptosis in vitro in many malignancies, including multiple myeloma (MM)...
  38. ncbi Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications
    Nicholas Mitsiades
    Department of Adult Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Blood 99:4525-30. 2002
    ..These studies both delineate the mechanism of action of IMiDs against MM cells in vitro and form the basis for clinical trials of these agents, alone and coupled with conventional and other novel therapies, to improve outcome in MM...
  39. ncbi Role of alpha 4 integrin (CD49d) in the pathogenesis of diabetic retinopathy
    Eirini Iliaki
    Angiogenesis Laboratory, Massachusetts Eye and Ear Infirmary, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts 02114, USA
    Invest Ophthalmol Vis Sci 50:4898-904. 2009
    ..The authors have now studied the role of integrin alpha 4/CD49d in the pathogenesis of diabetic retinopathy...
  40. ncbi Microenvironmental influence on pre-clinical activity of polo-like kinase inhibition in multiple myeloma: implications for clinical translation
    Douglas W McMillin
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, United States of America
    PLoS ONE 6:e20226. 2011
    ..clinical efficacy in MM and other cancers...
  41. ncbi Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
    Paul G Richardson
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 116:679-86. 2010
    ..Lenalidomide-bortezomib-dexamethasone demonstrates favorable tolerability and is highly effective in the treatment of newly diagnosed myeloma. This study is registered at http://clinicaltrials.gov as NCT00378105...
  42. ncbi Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myeloma
    Jana Jakubikova
    Jerome Lipper Multiple Myeloma Center, Dept of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston MA 02115, USA
    Haematologica 96:1170-9. 2011
    ..The growing body of preclinical information on the anti-cancer activity of isothiocyanates led us to investigate their anti-myeloma properties...
  43. ncbi Novel biologically based therapies for Waldenstrom's macroglobulinemia
    Constantine S Mitsiades
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA
    Semin Oncol 30:309-12. 2003
    ..These molecular studies provide a framework for rational design of the next generation of combination therapies for WM...
  44. ncbi Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications
    Nicholas Mitsiades
    Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Blood 99:4079-86. 2002
    ..These studies provide the framework for targeting NF-kappaB activity in novel biologically based therapies for MM...
  45. ncbi Nuclear factor-kappaB p65 mediates tumor necrosis factor alpha-induced nuclear translocation of telomerase reverse transcriptase protein
    Masaharu Akiyama
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Res 63:18-21. 2003
    ..These studies suggest that NF-kappaB p65 plays a pivotal role in regulating telomerase by modulating its nuclear translocation...
  46. ncbi Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells
    Vassiliki Poulaki
    Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts 02114, USA
    Am J Pathol 161:643-54. 2002
    ..T helper-1 cytokines and compounds that selectively abrogate the IGF-1 signaling pathway may be helpful adjunct agents in Apo2L/TRAIL-based anti-cancer therapeutic regimens...
  47. ncbi Constitutive nuclear factor-kappaB activity is crucial for human retinoblastoma cell viability
    Vassiliki Poulaki
    Retina Research and Angiogenesis Laboratory, Massachusetts Eye and Ear Infirmary, Harvard Medical School, 325 Cambridge Street, Boston, MA 02114, USA
    Am J Pathol 161:2229-40. 2002
    ..Therapeutic strategies targeting NF-kappaB could be beneficial in the clinical management of Rb, either alone or in combination with conventional chemotherapy...
  48. ncbi Methyljasmonate displays in vitro and in vivo activity against multiple myeloma cells
    Steffen Klippel
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA
    Br J Haematol 159:340-51. 2012
    ..1S cells compared to vehicle-treated mice (P = 0·0046). These studies indicate that jasmonates represent a new, promising strategy to treat MM...
  49. ncbi Molecular sequelae of histone deacetylase inhibition in human malignant B cells
    Nicholas Mitsiades
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Blood 101:4055-62. 2003
    ....
  50. ncbi Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma
    Paul G Richardson
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 27:5713-9. 2009
    ..This phase I, dose-escalation study (ie, NCT00153933) evaluated safety and determined the maximum-tolerated dose (MTD) of lenalidomide plus bortezomib in patients with relapsed or with relapsed and refractory MM...
  51. ncbi Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agents
    Merav Leiba
    Department of Medical Oncology, The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Harvard Medical School, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Br J Haematol 157:718-31. 2012
    ..Taken together, these preclinical studies provide the preclinical framework for future clinical studies of HF in MM...
  52. ncbi The Medical Research Council Myeloma IX trial: the impact on treatment paradigms
    Paul G Richardson
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Eur J Haematol 88:1-7. 2012
    ....
  53. ncbi Novel therapies in the treatment of multiple myeloma
    Jacob P Laubach
    Harvard Medical School and Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    J Natl Compr Canc Netw 7:947-60. 2009
    ..In aggregate, the use of novel therapies in MM has been associated with substantial improvements in patient outcome...
  54. ncbi Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity
    Douglas W McMillin
    1 Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA 2 Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts, USA 3 Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Nat Med 16:483-9. 2010
    ....
  55. ncbi Insulin-like growth factor-I plays a pathogenetic role in diabetic retinopathy
    Vassiliki Poulaki
    Retina Research Institute, Massachusetts Eye and Ear Infirmary, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Am J Pathol 165:457-69. 2004
    ..Taken together, these in vitro and in vivo signaling studies thus identify potential targets for pharmacological intervention to preserve vision in patients with diabetes...
  56. ncbi Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model
    Richard LeBlanc
    Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Res 62:4996-5000. 2002
    ....
  57. ncbi Molecular and cellular effects of NEDD8-activating enzyme inhibition in myeloma
    Douglas W McMillin
    Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA
    Mol Cancer Ther 11:942-51. 2012
    ..These studies provide the framework for the clinical investigation of MLN4924 in multiple myeloma...
  58. ncbi Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function
    Douglas W McMillin
    Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Blood 119:e131-8. 2012
    ..This study provides a framework to identify novel immunomodulatory agents and to prioritize compounds for clinical development on the basis of their effect on antitumor immunity...
  59. ncbi Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia
    Jacob P Laubach
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Leuk Lymphoma 50:694-702. 2009
    ....
  60. ncbi Cytokines modulate telomerase activity in a human multiple myeloma cell line
    Masaharu Akiyama
    Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Res 62:3876-82. 2002
    ..These studies therefore demonstrate that telomerase activity is associated with cell growth, survival, and drug resistance in MM cells...
  61. ncbi Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications
    Jana Jakubikova
    Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Department of Medical Oncology, Boston, MA, USA
    Blood 117:4409-19. 2011
    ..Our studies demonstrate a novel mechanism of action for lenalidomide, namely targeting SP fraction, providing the framework for new therapeutic strategies targeting subpopulations of MM cells including presumptive stem cells...
  62. ncbi Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study
    Paul G Richardson
    Dana Farber Cancer Institute, Boston, MA 02115
    Br J Haematol 150:438-45. 2010
    ..Tanespimycin monotherapy was well tolerated and demonstrated activity across all doses tested...
  63. ncbi Novel biological therapies for the treatment of multiple myeloma
    Paul G Richardson
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, MA, USA
    Best Pract Res Clin Haematol 18:619-34. 2005
    ....
  64. ncbi Novel therapies in myeloma
    Patrick J Hayden
    Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Curr Opin Hematol 14:609-15. 2007
    ..We summarize some of the trials leading to their approval and the current evidence for their clinical use. A number of promising agents undergoing phase I/II trial evaluation are also discussed...
  65. ncbi Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma
    Jacob P Laubach
    Dana Farber Cancer Institute, Department of Medical Oncology, 44 Binney Street, Boston, MA 02115, USA
    Expert Rev Hematol 4:51-60. 2011
    ..Combination regimens utilizing thalidomide, lenalidomide and bortezomib are also highlighted, as these regimens are likely to play an increasingly important role in myeloma therapy in the future...
  66. ncbi JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells
    Tanyel Kiziltepe
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Blood 110:709-18. 2007
    ..Taken together, these data provide the preclinical rationale for the clinical evaluation of JS-K to improve patient outcome in MM...
  67. ncbi Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells
    Nicholas Mitsiades
    Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Mayer Bldg, Boston, MA 02115, USA
    Blood 99:2162-71. 2002
    ..Our data set a framework for the clinical use of approaches that sensitize MM cells to TRAIL by agents that inhibit FLIP and cIAP-2 expression or augment caspase-8 activity...
  68. ncbi A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma
    Paul G Richardson
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Blood 108:3458-64. 2006
    ..Lenalidomide is active and well tolerated in relapsed, refractory myeloma, with the 30-mg once-daily regimen providing the basis for future studies as monotherapy and with dexamethasone...
  69. ncbi Proteomic analyses in Waldenstrom's macroglobulinemia and other plasma cell dyscrasias
    Constantine S Mitsiades
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA
    Semin Oncol 30:156-60. 2003
    ..These proteomic studies pave the way for a more comprehensive insight into the molecular basis of WM versus other B-cell malignancies...
  70. ncbi Focus on multiple myeloma
    Constantine S Mitsiades
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Cell 6:439-44. 2004
  71. ncbi Bortezomib in the management of multiple myeloma
    Jacob P Laubach
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Cancer Manag Res 1:107-17. 2009
    ....
  72. ncbi Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases
    Michael Koutsilieris
    Department of Experimental Physiology, Medical School, University of Athens, Goudi Athens, Greece
    Clin Cancer Res 10:4398-405. 2004
    ....
  73. ncbi Management of relapsed and relapsed/refractory multiple myeloma
    Jacob P Laubach
    Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA
    J Natl Compr Canc Netw 9:1209-16. 2011
    ..Moreover, the development of new drug classes based on preclinical rationale and the introduction of next-generation agents is likely to further expand treatment options and improve outcomes for relapsed MM...
  74. ncbi FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies
    Jing Chen
    Howard Hughes Medical Institute, Harvard Medical School, Boston, MA 02115, USA
    Oncogene 24:8259-67. 2005
    ..These data indicate that PKC412 may be a useful molecularly targeted therapy for MM associated with overexpression of FGFR3, and perhaps other diseases associated with dysregulation of FGFR3 or related mutants...
  75. ncbi The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions
    Constantine S Mitsiades
    Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street Boston, MA 02115, USA
    Eur J Cancer 42:1564-73. 2006
    ..g. lenalidomide), for the management of myeloma...
  76. ncbi Management of relapsed and relapsed refractory myeloma
    Efstathios Kastritis
    Department of Clinical Therapeutics, University of Athens, School of Medicine, 227 Kifissias Avenue, 14561 Kifissia, Athens, Greece
    Hematol Oncol Clin North Am 21:1175-215, x. 2007
    ....
  77. ncbi Molecular staging by RT-pCR analysis for PSA and PSMA in peripheral blood and bone marrow samples is an independent predictor of time to biochemical failure following radical prostatectomy for clinically localized prostate cancer
    Constantine S Mitsiades
    Department of Experimental Physiology, Medical School, University of Athens, Goudi-Athens, Greece
    Clin Exp Metastasis 21:495-505. 2004
    ..In clinically localized PrCa, combined PSA/PSMA RT-PCR in PBL and BM is an independent predictor of time to biochemical failure following radical prostatectomy...
  78. ncbi Thyroid carcinoma cells and Fas-mediated apoptosis
    Constantine S Mitsiades
    Thyroid 15:178-9. 2005
  79. ncbi Randomized controlled clinical trial of a combination of somatostatin analog and dexamethasone plus zoledronate vs. zoledronate in patients with androgen ablation-refractory prostate cancer
    Constantine S Mitsiades
    Department of Experimental Physiology, Medical School, University of Athens, Goudi-Athens, Attiki 115 27, Greece
    Anticancer Res 26:3693-700. 2006
    ....
  80. ncbi Effect of imatinib mesylate (Gleevec) on anaplastic thyroid carcinoma cell lines
    Constantine S Mitsiades
    J Clin Endocrinol Metab 88:5043-4; author reply 5044. 2003
  81. ncbi Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance
    Simona Blotta
    Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 114:3276-84. 2009
    ..These findings demonstrate OFD1 as an important immune target and highlight its possible role in signal transduction and tumorigenesis in MGUS and MM...
  82. ncbi CC-5013 (Celgene)
    Constantine S Mitsiades
    Dana Farber Cancer Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA
    Curr Opin Investig Drugs 5:635-47. 2004
    ....
  83. ncbi CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications
    Steven P Treon
    Department of Adult Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Immunother (1997) 25:72-81. 2002
    ..Furthermore, IFN-gamma induces CD20 expression on MM BMPCs and B cells and facilitates rituximab binding to MM BMPCs, providing the rationale for clinical trials to examine its use with CD20-directed serotherapies in MM...
  84. ncbi Male breast adenocarcinoma in a prostate cancer patient following prolonged anti-androgen monotherapy
    Peter Karamanakos
    Department of Surgery, Division of Surgical Oncology, Laikon General Hospital and University of Athens, 75 Micras Asias Street, Goudi, Athens, 11527, Greece
    Anticancer Res 24:1077-81. 2004
    ....
  85. ncbi From the bench to the bedside: emerging new treatments in multiple myeloma
    Constantine S Mitsiades
    Department of Medical Oncology, Harvard Medical School, Dana Farber Cancer Institute, 44 Binney St, Dana 1B02, Boston, MA 02115, USA
    Best Pract Res Clin Haematol 20:797-816. 2007
    ....